MSL
DNLI icon

Mackay Shields LLC’s Denali Therapeutics DNLI Stock Holding History

Mackay Shields LLC’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-22,400
Closed -$1.28M – 875
2021
Q1 		$1.28M Sell
22,400
-14,800
-40% -$991K 0.01% 926
2020
Q4 		$3.12M Buy
+37,200
New +$2.25M 0.02% 652
2020
Q2 		– Sell
-19,200
Closed -$337K – 1490
2020
Q1 		$337K Buy
+19,200
New +$401K ﹤0.01% 1206

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Mackay Shields LLC's DNLI Position: Q2 2021 in Review

Mackay Shields LLC sold out of Denali Therapeutics (DNLI) in Q2 2021, closing a stake of 22,400 shares — an estimated $1.28M sold.

Mackay Shields LLC first reported a position in DNLI in Q1 2020 and held it in 3 quarters. The position peaked at $3.12M in Q4 2020. 210 funds tracked by Wall St. Rank hold DNLI as of Q2 2021.

  • Mackay Shields LLC reported no remaining Denali Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 22,400 Denali Therapeutics shares in Q2 2021, an estimated $1.28M.
  • Mackay Shields LLC first reported a position in Denali Therapeutics in Q1 2020 and held it in 3 quarters.
  • Mackay Shields LLC's Denali Therapeutics position peaked at $3.12M in Q4 2020.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.